All In Biotech

Drug Trial Radar · NCT06014190

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

Dec 18, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Aug 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20089 as monotherapy in patients with recurrent or metastatic ovarian cancer and endometrial cancer.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
  • Endometrial Cancer

Interventions

  • HS-20089Drug

    All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Cancer Hospital

    Hefei, Anfei, China · Recruiting

  • Lingying Wu

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University cancer Hospital

    Chongqing, Chongqing Municipality, China · Suspended

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat-Sen Memorial Hospital Sun Yat-Sen University

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Hainan General Hospital

    Haikou, Hainan, China · Recruiting

  • The fourth Hospital of Heibei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Hubei Cancer University

    Wuhan, Hubei, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hosipital

    Changsha, Hunan, China · Recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China · Suspended

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Recruiting

  • The first Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Recruiting

  • Tianjin Medical University cancer institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Affiliated Cancer Hospital of Xinjiang Medical University

    Xinjiang, Xinjiang, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hanzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.